 |
 |
 |
| |
Mikael Ørum,
Partner |
 |
 |
| |
Peter
Damsbo, MD,
Partner |
 |
 |
| |
Robert L. Buchanan , PhD,
Attorney at Law, Partner |
|
Martin Austin,
Partner
|
 |
 |
| |
Dede Willis, BSc, MBA,
Partner |
 |
 |
| |
Mirko
Stange, PhD,
Partner |
 |
 |
| |
Madeline
Yap, PhD,
Partner |
 |
 |
| |
Konstantinos Alevizopoulos, PhD, Partner |
 |
 |
| |
Spencer Ma MBA, FCPA, ACIS ,
Partner |
 |
 |
| |
Bengt Westrin, PhD, Assoc. Professor,
Partner |
 |
 |
|
Peter Horn Moeller PhD,
Partner |
 |
 |
|
Aarti Kapoor,
M.S., MBA, Partner |
 |
 |
| |
Pieter
Telleman, PhD, MBA,
Senior Advisor |
 |
 |
| |
Lars Hedbys,
M Sc, PhD,
Senior Advisor |
 |
 |
| |
Christina Wagner, PhD,
Senior Advisor |
 |
 |
|
 |
| |
| |
|
|
Our Team
Mr. Martin Austin |
Partner
Martin Austin joined Ventac Partners as Partner in September 2010.
He has more than 35 years of senior executive experience from the
pharmaceutical industry, including the position as Head of Business
Development for the Pharmaceuticals Division at Hoffmann-La Roche,
from the international investment community as a Principal at Paul
Capital Partners Royalty Funds, a USA based specialist in Secondary
Private Equity and Alternative Asset Investments, as well as from
SME’s in the life sciences area. Areas of expertise include business
analysis, business planning and competitive intelligence functions,
M&A, equity investments, product divestments, and in- and
outlicensing on a large international scale. Since 2005, Martin
Austin has been Managing Director of TransformRx GmbH providing
business advice to clients regarding investment and business
development
He is the author of “Business Development for the Biotechnology and
Pharmaceutical Industry” 2008 based on the courses he presents with
CELforpharma (Brussels), Pharmaguys (Beijing), the World Intellectual
Property Organisation of the United Nations and at Basel University as a
part of the Masters in Drug Development Sciences degree course.
Martin Austin is a Partner in MarraM Advisors sarl, an Investment and
Fund Governance firm which is the sponsor of the BioIndustrial Finance
Fund (in formation), and MarraM BioMass which is developing projects in
microalgal oil production.
Martin Austin also serves as a Board Member of RSA AG the Swiss
subsidiary of the RSA Group. |
|

Martin Austin
Partner |
|
|